Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study

Roberto Latagliata; Dario Ferrero; Alessandra Iurlo; Francesco Cavazzini; Fausto Castagnetti; Elisabetta Abruzzese; Carmen Fava; Massimo Breccia; Mario Annunziata; Fabio Stagno; Mario Tiribelli; Gianni Binotto; Giovanna Mansueto; Antonella Gozzini; Sabina Russo; Laura Cavalli; Enrico Montefusco; Gabriele Gugliotta; Michele Cedrone; Antonella Russo Rossi; Paolo Avanzini; Patrizia Pregno; Endri Mauro; Antonio Spadea; Francesca Celesti; Gianfranco Giglio; Alessandro Isidori; Monica Crugnola; Elisabetta Calistri; Federica Sorà; Stefano Storti; Ada D'Addosio; Giovanna Rege-Cambrin; Luigiana Luciano; Giuliana Alimena

doi:10.1007/s40266-013-0088-6

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study

Roberto Latagliata, Dario Ferrero, Alessandra Iurlo, Francesco Cavazzini, Fausto Castagnetti, Elisabetta Abruzzese, Carmen Fava, Massimo Breccia, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Giovanna Mansueto, Antonella Gozzini, Sabina Russo, Laura Cavalli, Enrico Montefusco, Gabriele Gugliotta, Michele Cedrone, Antonella Russo RossiPaolo Avanzini, Patrizia Pregno, Endri Mauro, Antonio Spadea, Francesca Celesti, Gianfranco Giglio, Alessandro Isidori, Monica Crugnola, Elisabetta Calistri, Federica Sorà, Stefano Storti, Ada D'Addosio, Giovanna Rege-Cambrin, Luigiana Luciano, Giuliana Alimena

Research output: Contribution to journal › Article › peer-review

Abstract

Background: A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries. Patients and Methods: To describe the safety and tolerability of imatinib in very elderly CML patients in chronic phase, 211 chronic-phase CML patients aged >75 years were retrospectively analyzed using data collected from 31 institutions in Italy. Results: The median age at imatinib start was 78.6 years [interquartile range (IR) 76.3-81.4], median time from diagnosis to imatinib start was 1.2 months (IR 0.5-3.7). The starting dose of imatinib was 400 mg/day in 144 patients (68.2 %), >400 mg/day in 4 patients (2.0 %), and

Original language	English
Pages (from-to)	629-637
Number of pages	9
Journal	Drugs and Aging
Volume	30
Issue number	8
DOIs	https://doi.org/10.1007/s40266-013-0088-6
Publication status	Published - Aug 2013

ASJC Scopus subject areas

Pharmacology (medical)
Geriatrics and Gerontology

Access to Document

10.1007/s40266-013-0088-6

Cite this

Latagliata, R., Ferrero, D., Iurlo, A., Cavazzini, F., Castagnetti, F., Abruzzese, E., Fava, C., Breccia, M., Annunziata, M., Stagno, F., Tiribelli, M., Binotto, G., Mansueto, G., Gozzini, A., Russo, S., Cavalli, L., Montefusco, E., Gugliotta, G., Cedrone, M., ... Alimena, G. (2013). Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study. Drugs and Aging, 30(8), 629-637. https://doi.org/10.1007/s40266-013-0088-6

Latagliata, R, Ferrero, D, Iurlo, A, Cavazzini, F, Castagnetti, F, Abruzzese, E, Fava, C, Breccia, M, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Mansueto, G, Gozzini, A, Russo, S, Cavalli, L, Montefusco, E, Gugliotta, G, Cedrone, M, Russo Rossi, A, Avanzini, P, Pregno, P, Mauro, E, Spadea, A, Celesti, F, Giglio, G, Isidori, A, Crugnola, M, Calistri, E, Sorà, F, Storti, S, D'Addosio, A, Rege-Cambrin, G, Luciano, L & Alimena, G 2013, 'Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study', Drugs and Aging, vol. 30, no. 8, pp. 629-637. https://doi.org/10.1007/s40266-013-0088-6

@article{abd800acc3ef42d9addc08961603bcf9,

title = "Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study",

abstract = "Background: A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries. Patients and Methods: To describe the safety and tolerability of imatinib in very elderly CML patients in chronic phase, 211 chronic-phase CML patients aged >75 years were retrospectively analyzed using data collected from 31 institutions in Italy. Results: The median age at imatinib start was 78.6 years [interquartile range (IR) 76.3-81.4], median time from diagnosis to imatinib start was 1.2 months (IR 0.5-3.7). The starting dose of imatinib was 400 mg/day in 144 patients (68.2 %), >400 mg/day in 4 patients (2.0 %), and ",

author = "Roberto Latagliata and Dario Ferrero and Alessandra Iurlo and Francesco Cavazzini and Fausto Castagnetti and Elisabetta Abruzzese and Carmen Fava and Massimo Breccia and Mario Annunziata and Fabio Stagno and Mario Tiribelli and Gianni Binotto and Giovanna Mansueto and Antonella Gozzini and Sabina Russo and Laura Cavalli and Enrico Montefusco and Gabriele Gugliotta and Michele Cedrone and {Russo Rossi}, Antonella and Paolo Avanzini and Patrizia Pregno and Endri Mauro and Antonio Spadea and Francesca Celesti and Gianfranco Giglio and Alessandro Isidori and Monica Crugnola and Elisabetta Calistri and Federica Sor{\`a} and Stefano Storti and Ada D'Addosio and Giovanna Rege-Cambrin and Luigiana Luciano and Giuliana Alimena",

year = "2013",

month = aug,

doi = "10.1007/s40266-013-0088-6",

language = "English",

volume = "30",

pages = "629--637",

journal = "Drugs and Aging",

issn = "1170-229X",

publisher = "Springer International Publishing",

number = "8",

}

TY - JOUR

T1 - Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase

T2 - A retrospective study

AU - Latagliata, Roberto

AU - Ferrero, Dario

AU - Iurlo, Alessandra

AU - Cavazzini, Francesco

AU - Castagnetti, Fausto

AU - Abruzzese, Elisabetta

AU - Fava, Carmen

AU - Breccia, Massimo

AU - Annunziata, Mario

AU - Stagno, Fabio

AU - Tiribelli, Mario

AU - Binotto, Gianni

AU - Mansueto, Giovanna

AU - Gozzini, Antonella

AU - Russo, Sabina

AU - Cavalli, Laura

AU - Montefusco, Enrico

AU - Gugliotta, Gabriele

AU - Cedrone, Michele

AU - Russo Rossi, Antonella

AU - Avanzini, Paolo

AU - Pregno, Patrizia

AU - Mauro, Endri

AU - Spadea, Antonio

AU - Celesti, Francesca

AU - Giglio, Gianfranco

AU - Isidori, Alessandro

AU - Crugnola, Monica

AU - Calistri, Elisabetta

AU - Sorà, Federica

AU - Storti, Stefano

AU - D'Addosio, Ada

AU - Rege-Cambrin, Giovanna

AU - Luciano, Luigiana

AU - Alimena, Giuliana

PY - 2013/8

Y1 - 2013/8

N2 - Background: A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries. Patients and Methods: To describe the safety and tolerability of imatinib in very elderly CML patients in chronic phase, 211 chronic-phase CML patients aged >75 years were retrospectively analyzed using data collected from 31 institutions in Italy. Results: The median age at imatinib start was 78.6 years [interquartile range (IR) 76.3-81.4], median time from diagnosis to imatinib start was 1.2 months (IR 0.5-3.7). The starting dose of imatinib was 400 mg/day in 144 patients (68.2 %), >400 mg/day in 4 patients (2.0 %), and

AB - Background: A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries. Patients and Methods: To describe the safety and tolerability of imatinib in very elderly CML patients in chronic phase, 211 chronic-phase CML patients aged >75 years were retrospectively analyzed using data collected from 31 institutions in Italy. Results: The median age at imatinib start was 78.6 years [interquartile range (IR) 76.3-81.4], median time from diagnosis to imatinib start was 1.2 months (IR 0.5-3.7). The starting dose of imatinib was 400 mg/day in 144 patients (68.2 %), >400 mg/day in 4 patients (2.0 %), and

UR - http://www.scopus.com/inward/record.url?scp=84880850549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880850549&partnerID=8YFLogxK

U2 - 10.1007/s40266-013-0088-6

DO - 10.1007/s40266-013-0088-6

M3 - Article

C2 - 23681399

AN - SCOPUS:84880850549

VL - 30

SP - 629

EP - 637

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 8

ER -

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this